Who are Osimertinib Mesylate Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Osimertinib (Osi), Aumolertinib Oral Tablet, Cross-over to Osimertinib, HS-10241+ Almonertinib, AZD9291 Dosing, Osimertinib tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/osimertinib-mesylate-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Osimertinib Mesylate Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osimertinib Mesylate Tablets (Osimertinib Mesylate Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR tyrosine kinase inhibitor (third-generation). Area: Oncology.

phase 3 EGFR tyrosine kinase inhibitor (third-generation) EGFR (epidermal growth factor receptor), particularly mutant forms including T790M Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Osimertinib Mesylate Tablets (Osimertinib Mesylate Tablets) — Sun Yat-sen University. Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor that selectively targets EGFR mutations, including the T790M resistance mutation, in non-small cell lung cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Osimertinib Mesylate Tablets TARGET	Osimertinib Mesylate Tablets	Sun Yat-sen University	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (epidermal growth factor receptor), particularly mutant forms including T790M
Osimertinib (Osi)	Osimertinib (Osi)	AbbVie	marketed	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)
Aumolertinib Oral Tablet	Aumolertinib Oral Tablet	Shanghai Cancer Hospital, China	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)
Cross-over to Osimertinib	Cross-over to Osimertinib	AstraZeneca	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)
HS-10241+ Almonertinib	HS-10241+ Almonertinib	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)
AZD9291 Dosing	AZD9291 Dosing	AstraZeneca	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)
Osimertinib tablet	Osimertinib tablet	Shanghai JMT-Bio Inc.	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR tyrosine kinase inhibitor (third-generation) class)

AstraZeneca · 2 drugs in this class
AbbVie · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Shanghai Cancer Hospital, China · 1 drug in this class
Shanghai JMT-Bio Inc. · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Osimertinib Mesylate Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/osimertinib-mesylate-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing